Life science research and diagnostics solutions provider Bruker Corporation (Nasdaq:BRKR) has introduced CellScape XR, a next-generation spatial proteomics platform designed to enhance diagnostic and prognostic assay development, the company announced on Wednesday.

The system delivers high-throughput, reproducible, and quantitative spatial proteomics, addressing bottlenecks in translational research.

CellScape XR combines advances in optics, fluidics, and protocols to provide highly multiplexed protein detection with improved workflow flexibility, without compromising spatial resolution or data quality. The platform supports assay reproducibility and standardisation across large clinical cohorts.

Bruker has partnered with institutions including University Hospital Schleswig-Holstein, Kiel, where over 1,000 clinically annotated samples have been analysed, with plans to expand to around 3,000 patient samples.

The launch reinforces Bruker's focus on enabling spatial proteomics from discovery through translational research to clinical assay development. By providing scalable, quantitative spatial analysis, CellScape XR aims to accelerate the creation of next-generation diagnostics and prognostics that reflect the spatial complexity of disease biology.